13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-10-23 Event 2026-10-05 SEC 0001213900-26-112224 →

Simpson Andrew → HeartSciences Inc. HSCSW

Stake: 7.50% Shares: 403,739 CUSIP: 42254E104 Class: Common Stock, $0.001 par value per share
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 28/100
  • Active Schedule 13D filer baseline
  • High conviction ownership stake (7.5%)
  • Material 8-K governance/transaction event (Item 5.02 / 1.01 / 2.01) within ±30d

Item 4 — Purpose of Transaction

All of the shares of Common Stock and other securities of the Issuer reported herein (collectively, the "Securities") were acquired for investment purposes. The Reporting Person intends to evaluate their investment in the Securities on a continual basis. Other than as expressly set forth below, the Reporting Person have no plans or proposals as of the date of this filing that relate to, or would result in, any of the actions enumerated in Item 4(a)-(j) of Schedule 13D. The Reporting Person may engage in communications with one or more stockholders, officers or directors of the Issuer and others, including but not limited to, discussions regarding the Issuer's operations and strategic direction and ideas that, if effected, could result in, among other things, any of the matters identified in Item 4(a)-(j) of Schedule 13D, including but not limited to debt or equity capital raising transactions, acquisitions, mergers, combinations and other strategic transactions. The Reporting Person reserve their right, based on all relevant factors and subject to applicable law, at any time and from time to time, to review or reconsider their position, change their purpose, take other actions, including to cause or introduce strategic or corporate transactions involving the Issuer or any of its subsidiaries, or one or more of the types of transactions or have one or more the results described in Item 4(a)-(j) of Schedule 13D) or formulate and implement plans or proposals with respect to any of the foregoing. The Reporting Person from time to time intends to review their investment in the Issuer on the basis of various factors, including whether various strategic transactions have occurred or may occur, the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's securities in general, as well as other developments and other investment opportunities. Based upon such review, the Reporting Person intend to take such actions in the future as they deem appropriate in light of the circumstances existing from time to time, which may include acquisitions of shares of Common Stock or other convertible securities of the Issuer or disposal of all or any portion of the Securities or shares of Common Stock or other securities of the Issuer otherwise acquired by the Reporting Person, either in the open market or privately negotiated transactions, with or without prior notice.

Cross-References

Insider Activity (last 365d)
1 transaction
1 buys · 0 sales · 0 awards/exercises
Issuer Cluster
3 13D/G filings on this issuer
2 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 1.00
1,131 shares short · -10.3% vs prior

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-07-07 Watson Danielle officer Award 25,000 — —

Other 13D/G Filings on HeartSciences Inc.

FiledFormFilerStakeShares
2026-08-18 SCHEDULE 13D Digital Currency Group, Inc. — 411,522 view →
2026-06-24 SCHEDULE 13G Fields Ephraim G — — view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →